Lysosomal Storage Disorders Therapeutics
1. Cerdelga patent expiration
Treatment: Treatment of gaucher disease type 1; Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent ...
CERDELGA's oppositions filed in EPO
CERDELGA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6916802 | GENZYME CORP | Amino ceramide-like compounds and therapeutic methods of use |
Apr, 2022
(3 years ago) | |
| US7196205 | GENZYME CORP | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
Jun, 2026
(5 months from now) | |
| US11458119 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Nov, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7615573 | GENZYME CORP | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
Apr, 2022
(3 years ago) | |
| US7253185 | GENZYME CORP | Amino ceramide-like compounds and therapeutic methods of use |
Apr, 2022
(3 years ago) | |
| US12465586 | GENZYME CORP | NA |
Jun, 2032
(6 years from now) | |
| US10888547 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Jan, 2031
(5 years from now) | |
| US10888544 | GENZYME CORP | Methods for treating Gaucher disease |
Dec, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2019 |
| Orphan Drug Exclusivity(ODE) | Aug 19, 2021 |
| Orphan Drug Exclusivity(ODE-73) | Aug 19, 2021 |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
NCE-1 date: 19 August, 2018
Market Authorisation Date: 19 August, 2014
Dosage: CAPSULE
How can I launch a generic of CERDELGA before it's drug patent expiration?
More Information on Dosage
CERDELGA family patents
2. Galafold patent expiration
Treatment: The treatment of fabry patients; A method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat
GALAFOLD's oppositions filed in EPO
Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12280042 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11903938 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Aug, 2038
(12 years from now) | |
| US12042489 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11304940 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US12109205 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11612594 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US12042488 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11357764 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11376244 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11612593 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11622962 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Mar, 2039
(13 years from now) | |
| US11357765 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11426396 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11633387 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11826360 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Feb, 2039
(13 years from now) | |
| US11786516 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9000011 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(1 year, 4 months from now) | |
| US10383864 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(1 year, 4 months from now) | |
| US10471053 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10076514 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(11 years from now) | |
| US8592362 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(3 years from now) | |
| US11642334 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Feb, 2039
(13 years from now) | |
| US9095584 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(3 years from now) | |
| US9999618 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(2 years from now) | |
| US11458128 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10406143 | AMICUS THERAP US | Methods for treatment of fabry disease |
May, 2027
(1 year, 4 months from now) | |
| US10525045 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(2 years from now) | |
| US9987263 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(1 year, 4 months from now) | |
| US9480682 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(1 year, 4 months from now) | |
| US10925866 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(2 years from now) | |
| US10251873 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10813921 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(3 years from now) | |
| US11633388 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Mar, 2039
(13 years from now) | |
| US11033538 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(2 years from now) | |
| US12042490 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11357761 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11357762 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11357763 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11357784 | AMICUS THERAP US | Use of migalastat for treating Fabry disease in pregnant patients |
Feb, 2039
(13 years from now) | |
| US11666564 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10857141 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10849890 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10849889 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10857142 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| USRE48608 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Oct, 2031
(5 years from now) | |
| US11389437 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11389436 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10874657 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10874655 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10874656 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10792278 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10792279 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10799491 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US10806727 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11833164 | AMICUS THERAP US | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
Jan, 2042
(16 years from now) | |
| US11813255 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11234972 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(11 years from now) | |
| US11241422 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(1 year, 4 months from now) | |
| US11278538 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11278537 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11278536 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11278539 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| US11278540 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Dosage: CAPSULE
How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage
GALAFOLD family patents
3. Miplyffa patent
expiration
Treatment: Use of arimoclomol, in combination with miglustat, for treatment of neurological manifestations of niemann-pick disease type c (npc)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11045460 | ZEVRA DENMARK | Use of Hsp70 as a regulator of enzymatic activity |
Aug, 2029
(3 years from now) | |
| US9884058 | ZEVRA DENMARK | Use of Hsp70 as a regulator of enzymatic activity |
Jun, 2029
(3 years from now) | |
| US9289472 | ZEVRA DENMARK | Use of HSP70 as a regulator of enzymatic activity |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 20, 2029 |
| Orphan Drug Exclusivity(ODE-496) | Sep 20, 2031 |
Drugs and Companies using ARIMOCLOMOL CITRATE ingredient
NCE-1 date: 20 September, 2028
Market Authorisation Date: 20 September, 2024
Dosage: CAPSULE
More Information on Dosage
MIPLYFFA family patents
4. Zavesca patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5525616 | ACTELION | Method of inhibiting glycolipid synthesis |
Jun, 2013
(12 years ago) | |
| US5472969 | ACTELION | Method of inhibiting glycolipid synthesis |
May, 2013
(12 years ago) | |
Drugs and Companies using MIGLUSTAT ingredient
Market Authorisation Date: 31 July, 2003
Dosage: CAPSULE
More Information on Dosage
ZAVESCA family patents